A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

The findings suggest that there is a treatment window, potentially decades before symptoms are present, where those at risk of developing Huntington's disease are functioning normally despite ...

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine ... endpoint was reduced by the use of neuroleptic medications and VMAT2 inhibitor drugs used to control ...

In a recent study, beta blockers appeared to significantly lower both the annualized risk for conversion from presymptomatic to symptomatic Huntington’s disease (HD) and the rate of worsening ...

Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease (HD), scientists have ...

As a result, investigators have long sought to establish biomarkers earlier in the disease process to advance prevention and treatment ... in Huntington’s disease,” Tabrizi said.